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Objective: The purpose of this study was to evaluate the difference in objective measures of ambulation and psychosocial
factors in patients with intermittent claudication (IC) stratiﬁed by type D personality, which incorporates elements of
social inhibition and negative affectivity.
Methods: During a 1-year period, routine history and physical examination, ankle-brachial index, and pulse volume
recording were performed on IC patients. Questionnaires assessing type D personality and psychosocial factors were also
collected. The 6-minute walk test (6MWT) was performed, assessing symptoms and distance walked. Univariate and
multivariate methods were used to assess the association between ambulation and type D personality.
Results: Seventy-one patients were enrolled (mean age, 62.5 6 1.1 years; mean ankle-brachial index, 0.55 6 0.03). Mean
distance to symptoms and total distance walked were 83.7 6 80.1 m and 206.5 6 126.3 m, respectively. Type D per-
sonality was present in 29.6% of the population (n [ 21). On 6MWT, 83.1% of all patients developed symptoms, and
57.4% quit because of symptoms. Univariate analysis of objective measures of ambulation demonstrated lower distance to
symptoms in the type D group and trends toward lower total distance walked and quitting the 6MWT. Multivariate
models showed increased odds of quitting the 6MWT (odds ratio, 7.71; P [ .01) and less total distance walked by an
average of 33.2 6 13.3 m (P [ .02) for the type D group.
Conclusions: Despite equivalent demographic, medical, and psychosocial factors, the type D group was limited in
ambulation, suggesting that type D personality is a strong predictor of disease impact in patients with IC. (J Vasc Surg
2014;60:708-14.)There are an estimated 8 to 12 million persons in the
United States with peripheral arterial disease (PAD), and
a third of these have intermittent claudication (IC).1 These
patients often avoid physical activity secondary to pain,
which may lead to a decline in functional status and
health-related quality of life (HRQOL). Claudication dis-
tances and quality of life measures help determine the level
of impairment in patients with PAD.2 Depressive symp-
toms are associated with functional impairment, worsened
patency after lower extremity revascularization, and poorer
quality of life.3 Approximately 16% of patients with PAD
have reported signiﬁcant depressive symptoms in previous
research. These patients had a signiﬁcantly shorter
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Type D (or “distressed”) is a personality construct
introduced in 1995 by Denollet et al4 on the basis of prior
research on coping styles in patients with coronary artery
disease. This personality construct is made up of two
components: negative affectivity and social inhibition.
Negative affectivity is a tendency to experience negative
emotions. Social inhibition is inhibition of emotional
expression, increased insecurity in social situations, and
increased control of self-expression secondary to fear of
disapproval.5 The prevalence of type D personality is 19%
in the general population, 27% in those with coronary ar-
tery disease, and up to 54% in those with hypertension.6
Whereas there is some overlap between depression and a
type D personality, they are not equivalent. Type D is a sta-
ble personality trait, whereas depression is a diagnosable
psychiatric disorder that can be manifested with varying
levels of severity and types of chronicity and recurrence.
Type D also includes the element of social inhibition,
which is not a requisite for a diagnosis of depression.5
Most research on type D personality has been in popu-
lations with cardiac disease, in which it has been a risk factor
for negative outcomes. In patients recovering from acute
coronary syndrome, it is predictive of poor prognosis.7
There has been little research, however, in patients with
PAD. The research on the relation between psychosocial fac-
tors and PAD has shown associations with reduced
HRQOL, depressive symptoms, and all-cause mortality.5,8,9
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In this prospective cohort study, 71 patients seen in the
vascular surgery clinic between April 2012 and September
2013 with IC for their initial consultation were enrolled.
The initial goal to show signiﬁcance was 60 patients.
Patients were excluded if they had critical limb ischemia
or rest pain. This represents a baseline cross-sectional anal-
ysis of our population. The institutional review board
approved the protocol for this study as well as the informed
consent. All patients consented to participation.
Basic demographic information (age, gender, and race)
was recorded. Information on comorbid conditions was
obtained from chart review as well as by patient interview.
Comorbid conditions recorded were hypertension, coro-
nary artery disease, diabetes, chronic obstructive pulmo-
nary disease, hyperlipidemia, and end-stage renal disease.
Review of medications was undertaken with the patient
to record whether he or she was taking aspirin, beta
blocker, statin, angiotensin-converting enzyme inhibitor,
angiotensin receptor blocker, insulin, or cilostazol. Smok-
ing history and whether the patient was currently smoking
were also assessed on the patient interview.
Vital signs were taken at the visit, including blood pres-
sure in both upper extremities, weight, and body mass
index. Ankle-brachial index (ABI) and pulse volume
recording (PVR) were performed in both lower extremities
after 20 minutes of rest. The worse ABI and PVR were
used as the markers of severity of disease. Physical examina-
tion included pulse examination of carotid arteries, radial
arteries, femoral arteries, popliteal arteries, dorsalis pedal
arteries, and posterior tibial arteries.
The patients performed a 6-minute walk test (6MWT).
Patients walked with a trained observer. The 6MWT was
performed in a ﬂat hallway with marked distances. The pa-
tients had not previously done this in rehabilitation or
other training programs. They walked at their own pace
for 6 minutes or until the severity of symptoms precluded
them from continuing the test. The development of symp-
toms was recorded, including distance to onset of symp-
toms (PFWD). Total distance walked (MWD), total time
walked, and whether the patient quit the test early were
also recorded. Physiologic measures were not recorded
during the 6MWT. Patients with comorbidities limiting
ambulation were excluded from the 6MWT analysis but
remained in the study for the psychosocial measurements.
Quality of life was assessed with the Vascular Quality of
Life (VascuQoL) questionnaire. This is a validated quality
of life questionnaire for patients with peripheral vascular
disease that contains subscales for activity, symptoms,
pain, emotion, and social activity. It consists of 25 ques-
tions on a seven-point Likert scale.1 Walking impairment
was assessed with the Walking Impairment Questionnaire.
This questionnaire assesses limitations in walking distance
and speed in patients with claudication.1 The type D scale
(DS14) was used for assessment of type D personality. This
has subscales for negative affectivity and social inhibition,
with a patient being classiﬁed as type D if both negativeaffectivity and social inhibition are$10. The Hospital Anx-
iety and Depression Scale questionnaire was also assessed in
a pilot study of this population. The questionnaire was
given to the patient with the other psychosocial instru-
ments at the clinic visit. Patients unable to complete the
6MWT were not excluded because they could contribute
to the psychosocial portion of the study.
Univariate statistics were calculated to characterize the
general population. Correlations to time, distance to symp-
toms, total distance, and whether patients developed symp-
toms and quit before the full time in the 6MWT were
calculated. Correlation to the other variables on whether
a patient was type D and based on the scores of the individ-
ual type D subscales was assessed.
The average walking speed of each participant during
the 6MWT was calculated in meters per minute to account
for variations in walking speed. Correlations with PVR,
development of symptoms, distance to symptoms, total dis-
tance, early termination of the 6MWT, and type D person-
ality were calculated.
To conﬁrm that ABI and PVR were correlated, analysis
of variance was used to compare mean ABI of each PVR
group (normal/mild, moderate, severe). Tukey test was
then applied to ensure differences between the three PVR
groups. ABI was used in the multivariate regressions.
Multivariate regression models were constructed for
6MWT outcomes beginning with all variables that trended
toward correlation (P < .20) and using backward selection
to arrive at the ﬁnal model. Logistic regression models were
constructed with the end points of development of symp-
toms and quitting the 6MWT early because of symptoms.
Multiple linear regression models with the outcomes of
distance to development of symptoms and total distance
walked were also constructed. For signiﬁcant models, the
model was again constructed as before with the addition of
depression scores as a linear variable and as a binary variable
based on the standard cutoff for depression. Backward selec-
tionwas employed in all instances to arrive at the ﬁnalmodel.
RESULTS
Our population consisted of 71 patients with IC. They
had amean age of 62.56 1.1 years. Five (7.0%) had an oper-
ation for cardiac revascularization within a 3-year window of
this study, with two of those patients in the type D group.
Population ﬁndings on demographics, comorbidities, med-
ications, prior procedures, ABI and PVR, 6MWT, and ques-
tionnaire results can be found in Table I. Three patients
were unable to perform the walk test because of comorbid-
ities and were excluded from this part of the analysis. Of
those who began the 6MWT, 86.8% developed symptoms
and 57.5% quit before 6 minutes because of symptoms.
The patients walked a mean distance of 206.5 6 15.3 m.
The mean distance to the development of symptoms for
those who developed symptoms was 83.7 6 10.4 m.
Univariate analysis. Univariate comparisons between
the type D population (n ¼ 21) and nontype D popula-
tion (n ¼ 50) are illustrated in Table II. There were no
Table I. Total population characteristics
Demographics
Age, years 62.5 6 1.1
Gender, male 44/71 62.0%
Race
African American 25 35.2%
White 45 63.4%
Other 1 1.4%
Comorbidities
Hypertension 55/71 77.5%
COPD 14/71 19.7%
CAD 29/71 40.8%
Diabetes 25/71 35.2%
ESRD 1/71 1.4%
Hyperlipidemia 45/71 63.4%
Smoking
Smoking history 65/71 91.5%
Current smoker 46/71 64.8%
Medications
Aspirin 51/70 72.9%
Beta blocker 27/70 38.6%
Statin 50/70 71.4%
ACE inhibitor 20/70 28.6%
ARB 18/52 25.7%
Insulin 8/70 11.4%
Prior procedures
Prior open procedure 10/71 14.1%
Prior endovascular procedure 19/71 26.8%
Physical examination
BMI, kg/m2 28.6 6 7.8
ABI 0.55 6 0.03
PVR
Normal/mild 16 24.6%
Moderate 18 27.7%
Severe 31 47.7%
6MWT
6MWT developed symptoms 59/68 86.8%
6MWT quit 39/68 57.5%
6MWT PFWD, m 83.7 6 10.4
6MWT MWD, m 206.5 6 15.3
6MWT total time, minutes 3.95 6 0.24
Questionnaires
VascuQoL activity 3.43 6 1.34
VascuQoL symptoms 4.00 6 0.16
VascuQoL pain 3.65 6 0.17
VascuQoL emotion 4.56 6 0.18
VascuQoL social 4.37 6 0.21
VascuQoL total 3.95 6 0.15
WIQ distance 20.0% 6 2.9%
WIQ speed 23.4% 6 2.8%
Negative affectivity 9.5 6 0.9
Social inhibition 8.0 6 0.8
Type D 21/71 29.6%
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
BMI, body mass index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; ESRD, end-stage renal disease; MWD,
maximum walking distance; 6MWT, 6-minute walk test; PFWD, pain-free
walking distance; PVR, pulse volume recording; VascuQoL, Vascular
Quality of Life questionnaire; WIQ, Walking Impairment Questionnaire.
Continuous data are presented as mean 6 standard deviation.
Table II. Univariate comparisons between type D group
and nontype D group
Type D
(n ¼ 21)
Nontype D
(n ¼ 50) P
Demographics
Age, years 60.9 6 2.0 63.1 6 1.4 .36
Gender, male 12/21 (57.1) 32/50 (64.0) .59
Race .68
African American 7 (33.3) 18 (36.0)
White 14 (66.7) 31 (62.0)
Other 0 (0.0) 1 (2.0)
Comorbidities
Hypertension 18/21 (85.7) 37/50 (74.0) .27
COPD 4/21 (19.1) 10/50 (20.0) .93
CAD 9/21 (42.9) 20/50 (40.0) .82
Diabetes 8/21 (38.1) 17/50 (34.0) .74
ESRD 0/21 (0.0) 1/50 (2.0) .40
Hyperlipidemia 12/21 (57.1) 33/50 (66.0) .48
Smoking
Smoking history 20/21 (95.2) 45/50 (90.0) .45
Current smoker 15/21 (71.4) 31/50 (62.0) .44
Medications
Aspirin 14/21 (66.7) 37/49 (75.5) .45
Beta blocker 9/21 (42.9) 18/49 (36.7) .63
Statin 13/21 (61.9) 37/49 (75.5) .26
ACE inhibitor 2/21 (9.5) 18/49 (36.7) .01
ARB 8/21 (38.1) 10/49 (20.4) .13
Cilostazol 4/21 (19.1) 5/49 (10.2) .33
Insulin 4/21 (19.1) 4/49 (8.2) .21
Prior procedures
Prior open procedure 4/21 (19.1) 6/50 (12.0) .45
Prior endovascular
procedure
10/21 (47.6) 9/50 (18.0) .01
Physical examination
BMI, kg/m2 29.1 6 1.15 28.4 6 1.22 .67
ABI 0.55 6 0.26 0.55 6 0.19 .54
PVR .62
Normal/mild 6 (31.6) 10 (21.7)
Moderate 5 (21.0) 14 (30.4)
Severe 9 (47.4) 22 (47.8)
6MWT
6MWT developed
symptoms
16/21 (76.2) 43/50 (86.0) .33
6MWT quit 14/20 (70.0) 25/48 (52.1) .17
6MWT PFWD, m 57.4 6 12.3 87.3 6 13.3 .03
6MWT MWD, m 170.3 6 25.0 221.6 6 18.8 .05
6MWT total time,
minutes
3.37 6 0.45 4.20 6 0.28 .06
Questionnaires
VascuQoL activity 3.38 6 0.26 3.46 6 0.20 .80
VascuQoL symptoms 4.18 6 0.25 3.93 6 0.21 .45
VascuQoL pain 3.69 6 0.31 3.64 6 0.21 .89
VascuQoL emotion 4.52 6 0.28 4.59 6 0.23 .85
VascuQoL social 4.55 6 0.35 4.30 6 0.26 .57
VascuQoL total 3.97 6 0.25 3.95 6 0.19 .95
WIQ distance 22.0% 6 6.8% 19.6% 6 3.1% .75
WIQ speed 22.6% 6 5.6% 24.6% 6 3.2% .76
Negative affectivity 15.1 6 1.2 7.1 6 0.9 <.0001
Social inhibition 14.4 6 7.4 5.4 6 0.8 <.0001
ACE, Angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
BMI, body mass index; CAD, coronary artery disease; COPD, chronic
obstructive pulmonary disease; ESRD, end-stage renal disease; MWD,
maximum walking distance; 6MWT, 6-minute walk test; PFWD, pain-free
walking distance; PVR, pulse volume recording; VascuQoL, Vascular
Quality of Life questionnaire; WIQ, Walking Impairment Questionnaire.
Continuous data are presented as mean 6 standard deviation and
categorical data as n/N (%).
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mographics, comorbidities, or baseline ABI and PVR. There
was no correlation between type D personality and gender
(P ¼ .59), type D personality and depression (P ¼ .17), or
gender and depression (P ¼ .9). The type D group was less
likely to be receiving an angiotensin-converting enzyme
Table III. Logistic regression for quit for symptoms
Variable OR 95% CI P
Prior open 0.04 0.001-0.51 .01
Statin 8.67 1.63-65.1 .01
ARB 6.19 1.25- 47.8 .02
Worse ABI 1.07 1.03-1.12 .0001
Type D 7.71 1.59-54.6 .01
ABI, Ankle-brachial index; ARB, angiotensin receptor blocker; CI,
conﬁdence interval; OR, odds ratio.
Model P ¼ .0001.
Table IV. Linear regression to maximum walking
distance (MWD) on 6-minute walk test (6MWT)
Term Estimate SE P
Intercept 66.7 35.6 .07
Female 40.5 12.4 .002
Prior open 58.4 18.2 .002
ABI 2.97 55.8 <.0001
Type D 33.2 13.3 .02
ABI, Ankle-brachial index; SE, standard error.
Model P < .0001.
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36.7% of the nontype D group (P ¼ .01). Seven of the pa-
tients (9.9%) were taking selective serotonin reuptake in-
hibitors, which was too small a sample to investigate for
statistical signiﬁcance. The type D group was also more
likely to have had a prior endovascular procedure, with
47.6% having had a prior endovascular intervention
compared with 18.0% of the nontype D group (P ¼ .01).
Patients taking statins showed trends toward older age
of 63.5 6 7.2 years compared with 59.9 6 10.3 years for
those not taking statins (P ¼ .10). They also showed a
trend toward development of symptoms on the 6MWT,
with 88% of patients taking statins developing symptoms
compared with 70% of those not taking statins (P ¼ .08).
Those taking statins were more likely to have hypertension
(84% compared with 60%; P ¼ .04) and coronary artery
disease (54% compared with 10%; P ¼ .0003).
The mean walking speed was 52.66 2.0 m/min. There
was no association between walking speed and PVR (P ¼
.75) or early termination of the 6MWT (P ¼ .79). Mean
walking speed for the type D group was 52.7 6 3.4 m/s
compared with a mean walking speed of 52.5 6 2.4 m/s
for the nontype D group (P ¼ .97). The adjusted R2 for
the correlation between speed and MWD was 0.166 (P ¼
.0003), suggesting that 16.6% of the variation in walking
distance was accounted for by speed.
There were no signiﬁcant correlations between
angiotensin-converting enzyme inhibitor use and MWD
(P ¼ .71), PFWD (P ¼ .55), or quitting the 6MWT
(P ¼ .66). There were no signiﬁcant correlations between
prior endovascular procedures and MWD (P ¼ .26),
PFWD (P ¼ .88), or quitting the 6MWT (P ¼.20). On
the 6MWT, there was no signiﬁcant difference between
the type D and nontype D groups on the development of
symptoms, but therewas a trend toward signiﬁcance onquit-
ting the 6MWT early and total time walked. The type D
group performed signiﬁcantly worse on PFWD and MWD.
When patients who had a prior endovascular procedure
were excluded, there remained strong trends toward differ-
ences in early termination of the 6MWT, PFWD, and
MWD. In this set, 81.8% of type D patients (n ¼ 11) quit
the 6MWT early compared with 56.4% of the nontype
D group (n ¼ 39) (P ¼ .11). The type D group had a
mean MWD of 145.5 6 25.8 m compared with 209.9 6
20.9 m for the nontype D group (P ¼ .06). The PFWD
for the type D group was 57.3 6 17.2 m compared with
92.0 6 14.6 m for the nontype D group (P ¼ .14).
There were no signiﬁcant differences between the type D
and nontype D groups on the VascuQoL questionnaire or
Walking Impairment Questionnaire. On the DS14, the
mean negative affectivity was 15.16 1.2 for the typeD group
and 7.1 6 0.9 for the nontype D group (P < .0001). The
mean social inhibition was 14.4 6 7.4 for the type D group
and 5.46 0.8 for the nontype D group (P < .0001).
Comparison of ABI and PVR. PVR classiﬁcations as
normal/mild, moderate, and severe were validated by
comparing mean ABI with signiﬁcant differences between
groups.Logistic regression. On logistic regression, type D was
not associated with signiﬁcantly increased odds of symptom
development during 6MWT (P ¼ .93). However, logistic
regression indicated that typeDpersonalitywas related to ter-
minating the 6MWT early because of symptoms. Speciﬁcally,
typeDwas associatedwith7.71 times increase inodds of quit-
ting the 6MWT early (95% conﬁdence interval, 1.59-54.6)
compared with the nontype D group in controlling for other
factors associated with differences in the 6MWT (Table III).
Linear regression. On multiple linear regression for
PFWD, the type D group walked 15.9 m less on average,
although this was not signiﬁcant (P ¼ .16). On a second
multiple linear regression for MWD, the type D group
walked 33.2 m less on average than the nontype D group
(P ¼ .02) in controlling for other factors associated with
6MWT outcomes (Table IV).
Controlling for depression. The statistical inﬂuence
of depression was assessed in both models in which type
D personality was signiﬁcant. Depression was not signiﬁ-
cantly correlated with the outcome (P > .20) and did
not alter the model appreciably in either instance.
DISCUSSION
Despite a relatively small sample, these data support a
signiﬁcant association between type D personality and wors-
enedperformance in ambulation.This is signiﬁcant because a
patient’s perception of his or her health helps guide treat-
ment in PAD.1 The typeD and nontypeDgroup were com-
parable in demographics, comorbidities, and baseline ABI
and PVR. There was also no signiﬁcant difference in the
development of symptoms during the 6MWT. However,
there were differences in MWD and the odds of
completing the 6MWT. Whereas walking speed did ac-
count for a signiﬁcant amount in the variability in
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the two groups, and this variable did not act as a
confounder. Interestingly, we were unable to reproduce
the results of lower quality of life that has been demon-
strated in this population in prior studies.8 This may be
related to differences in rating instruments. The prior
study used the World Health Organization Quality of
Life questionnaire, which is a more general quality of
life instrument, whereas the measure we used (VascuQoL
questionnaire) is more focused on disease-speciﬁc quality
of life. The possibility that differences in quality of life
previously seen are based on factors not related to vascular
disease exists, but this is beyond the scope of this analysis.
The high proportion of prior endovascular interven-
tions in the type D group raises concerns that this is a sepa-
rate group that may have different functional outcomes.
Two factors ease those concerns. The ﬁrst is that within
our data, there was no association between a prior endovas-
cular procedure and worse outcomes on the 6MWT. The
second is that when only patients who had not had a prior
endovascular procedure were included, the trends toward
worse outcomes for the type D group remain. Although
they lose statistical signiﬁcance in this group, this may be
a result of losing nearly a third of the sample.
Other interesting ﬁndings include the increased odds of
poor performance on the 6MWT for those taking statins
and the dramatically improved 6MWT performance for
those who had a prior open procedure. Patients taking sta-
tins showed a trend toward being older and more likely to
develop symptoms. They were also signiﬁcantly more likely
to have hypertension and coronary artery disease. Given
these facts and what is known about the role of statins in car-
diovascular disease, it appears that statins serve as a marker
of disease and not a risk factor. Those who are taking statins
are taking them because they have other risk factors for
PAD, whichmay result in a worse performance on a 6MWT.
Although there is a profound decrease in the odds of
early termination of the 6MWT for patients who had a
prior open procedure, we would caution that this should
not be taken as an argument for increased use of open sur-
gery in patients with IC. Intervention is indicated when the
degree of functional impairment due to IC is clinically sig-
niﬁcant.10 Because the study was not set up to evaluate the
role of open surgery in IC, the signiﬁcantly improved odds
of completing the 6MWT do not mean that the group who
had not had a prior procedure is functionally impaired to
the degree of needing surgery.
Type D personality is composed of two traits, negative
affectivity (the tendency to experience negative emotions
across time and situation) and social inhibition (the tendency
to inhibit expression of emotion in social interactions for fear
of disapproval). Both must be present to a certain degree for
a person to be categorized as type D on the basis of DS14
scores.6 The differences in these traits between the type D
and nontype D populations are evident with mean negative
affectivity and social inhibition scores of the two groups.
There is evidence that these features are stable over time.11
Data in patients with cardiac disease show that it is notconfounded by changes in mood or depressive symptoms,
and recent data have raised the possibility of heritability.12
This personality type may be related to emotion processing
on the basis of differences seen in neuroimaging studies.13
Negative emotions may be related to PAD. This is sig-
niﬁcant because up to one of three patients with PAD may
suffer from subclinical depression.3 Depression and vascular
disease may exacerbate each other; depression may predis-
pose one to and worsen vascular disease, whereas vascular
disease may engender or worsen depression.3 A study exam-
ining negative emotions (depression, anxiety, and anhe-
donia) and symptoms of PAD found that anxiety was less
prevalent in asymptomatic patients, with increasing preva-
lence as symptoms increased.14 Asymptomatic patients
also had the lowest rates of depression and anhedonia.14
Type D personality is associated with risk of depression.
It may predict development of depression and persistence
of depressive symptoms in controlling for baseline depres-
sion.12 The propensity to negative affectivity may explain
some of the effects on ambulatory outcomes, although it
is important to keep in mind that depression and type D
personality are distinct constructs. Ultimately we found
that type D personality was an independent predictor of
worsened ambulatory outcomes, whereas depression was
not statistically signiﬁcant. This independence of type D
from mood disorders is also evident in the cardiac litera-
ture.15 In looking at fatigue in patients with ischemic heart
disease, type D was found to be a predictor of fatigue inde-
pendent of stage.16 Type D is an independent risk factor
for cardiovascular mortality after myocardial infarction.17
There may be physiologic and behavioral reasons for
the worsened outcomes in patients with type D personality
and cardiovascular disease. Evidence of altered physiology
can be seen in increased tumor necrosis factor-a in patients
with congestive heart failure.18 There is also evidence of
increased cortisol, which is a risk factor for cardiovascular
disease.19 In a sample of 70 middle-aged subjects without
cardiovascular disease or major risk factors, 48.6% of type
D subjects had abnormal carotid intimal thickness
compared with just 22.9% of controls (P ¼ .001).20
Type D persons also display behaviors and beliefs that
may be related to their adverse outcomes. They have lower
levels of perceived social support.21 Their coping mecha-
nisms are more likely to be passive and maladaptive, with
resignation and withdrawal being highly used.21 Compared
with patients who are not type D, they tend to believe that
their disease will last longer and is less controllable by them-
selves or treatment. They also have been shown to demon-
strate fewer health-related behaviors, are less likely to
report symptoms to the medical team, and are more likely
to be noncompliantwith therapy.21 It is difﬁcult to gauge pa-
tient effort during the 6MWT. Given the poor compliance,
coping mechanisms, and health behaviors associated with
type D personality, it is possible that lack of effort is a medi-
ating effect for the outcomes of this group on the 6MWT.
This seems to be a subset of the population that is less
tolerant of its symptoms. This may explain why they are
more likely to have had a prior endovascular procedure.
JOURNAL OF VASCULAR SURGERY
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management and response to interventional treatment.
Additional possible avenues for investigation include nontra-
ditional therapy, such as teaching of new coping mecha-
nisms to replace the maladaptive behavior to see the effect
on outcomes. Whereas the personality type is not a modiﬁ-
able risk factor, the maladaptive coping mechanisms may be.
Knowing if type D personality results in different
treatment outcomes or if nontraditional treatments will
be found to be helpful in this group, there would be value
in identifying this subset of patients. The DS14 is a simple
tool that takes minimal time commitment to ﬁll out. In
addition, because type D personality is a stable factor, it
does not need to be reassessed in subsequent visits.
CONCLUSIONS
This is the ﬁrst study to examine the relation between
type D personality and ambulatory measures of IC. Despite
no signiﬁcant differences in demographics, comorbidities,
baseline ABI, and development of symptoms, the type D
subset of our sample performed worse on objective ambula-
tory measures, which was an effect that was statistically inde-
pendent of depression. We were unable to replicate
the reduced HRQOL seen in prior studies; however, the
quality of life assessment used was the more vascular focused
VascuQoL questionnaire as opposed to the more general
World Health Organization Quality of Life questionnaire
previously used, which may account for this discrepancy.
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Submitted Jan 24, 2014; accepted Mar 25, 2014.DISCUSSIONDr Matthew A. Corriere (Winston-Salem, NC). I would like
to thank Dr Torrent and his colleagues at East Carolina for their
manuscript and appreciate their providing me with a draft in
advance of the meeting. The authors are to be commended forpursuing a creative hypothesis with a thoughtful prospective study
design that included objective physiologic outcomes. Associations
between psychological factors and clinical outcomes have been
increasingly recognized in coronary heart disease and other
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714 Torrent et al September 2014conditions, and it is great to see an analysis that explores these re-
lationships in patients with peripheral arterial disease. I have three
questions and some related comments.
First, can you help us interpret the results of the 6-minute
walk test? You noted an association between type D personality
and early termination of the test. I would assume that early termi-
nation is the result of symptoms, but type D personality was not
associated with symptom development during the test, and the
similar Vascular Quality of Life questionnaire results seem to sup-
port the notion that symptom severity was similar between groups.
How do we reconcile these observations? If the patients terminated
the test for some other reason, it would certainly be interesting to
know why. Given the associations between type D personality with
nonadherence and decreased healthy behaviors that you
mentioned in the discussion, it is plausible to suspect that fewer
type D patients would be compliant with a structured exercise pro-
gram; this is an important therapeutic consideration that would
potentially inﬂuence several of these outcomes but was not
included in your analysis. Alternatively, might we conclude that
type D personality is associated with just being more likely to quit?
Second, why did you select type D personality for comparison
vs all others, and did you evaluate any other personality types in
your analysis? I would certainly be interested to learn whether
other personalities have unique comorbidity proﬁles or ambulatory
outcomes and was wondering whether a single personality type as a
control (rather than all others combined) might provide a more
informative comparison.
Third, please expand on how these ﬁndings can potentially
help us take care of patients with intermittent claudication. Do
you regard type D personality as a modiﬁable risk factor? I was
wondering, on the basis of your results, if pharmacotherapy might
have potential to improve outcomes in these patients through ef-
fects on adherence or health-related behaviors. Accordingly, in
addition to aspirin, statins, and cilostazol, I would encourage
you to consider adding antidepressant and anxiolytic medications
to your analysis if those data are available; it would be interesting
to see if adjustment for these additional medications affected
your results in any way.
I would like to thank the Society for allowing me the privilege
of discussing this manuscript and would again like to thank DrTorrent and colleagues for taking us off the beaten path with
such an interesting and provocative analysis.
Dr Daniel J. Torrent. The type D group was not any more
likely to develop symptoms or to develop symptoms at a shorter
distance. However, when symptoms did develop, they were
more likely to quit. This may go back to the negative affectivity
and these patients being less hopeful about outcomes. This is
consistent with what we know about the personality type. It
does appear that they may be more likely to be “quitters.” In addi-
tion to not being more likely to develop symptoms, they did not
rate their symptoms any worse than their nontype D counterparts
did. It appears that they just handled their symptoms less well. This
personality type shows increased noncompliance and decreased
health behaviors. The next thing to look at will be how they do
with treatment. We are continuing to observe this cohort.
We selected the type D personality for study for two reasons.
The ﬁrst was that data during the last 15 years in patients with cor-
onary artery disease showed worse outcomes independent of other
factors. The second was that these patients tend to have a more
negative subjective interpretation of their symptoms, and intermit-
tent claudication is a disease process in which the patient’s subjec-
tive experience helps guide treatment.
We did not compare patients with type D personality with
other personality types because it is not mutually exclusive with
other types. It exists as its own construct. A person can be classiﬁed
as type A or B and also be type D.
Type D personality is not modiﬁable. As a personality trait, it is
stable over time and situation. However, there are associated be-
haviors that are modiﬁable. The major one is coping mechanisms.
Patients with type D personality use maladaptive coping mecha-
nisms. If they can be taught better ones, this may improve their
outlook and compliance. The other important aspect is being
aware that these patients are a subset of the population. As a group,
they were more likely to have had a prior endovascular procedure,
which is probably related to their being more likely to complain
that their symptoms are lifestyle limiting at a severity similar to
that of the nontype D patients.
We did look at selective serotonin reuptake inhibitor use, but
only seven of the 71 patients in the study were currently taking
these medications. This limited the power of statistical analysis.
